Does Ranibizumab (Lucentis®) Change Retrobulbar Blood Flow in Patients with Neovascular Age-Related Macular Degeneration?

Publisher： Karger

E-ISSN： 1423-0259|47|3|141-145

ISSN： 0030-3747

Source： Ophthalmic Research, Vol.47, Iss.3, 2011-10, pp. : 141-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration

By Patel Ravi D.   Momi Rominder S.   Hariprasad Seenu M.  

Seminars in Ophthalmology, Vol. 26, Iss. 6, 2011-11 ,pp. : 372-379

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Intraocular Pressure Changes in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab

By  

Ophthalmologica, Vol. 229, Iss. 3, 2013-03 ,pp. : 168-172

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity

By  

Ophthalmologica, Vol. 233, Iss. 1, 2014-11 ,pp. : 27-34

Karger

Access to resources Recommend Favorite